Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT04954625 Enrolling by invitation - Lung Cancer Clinical Trials

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

A postoperative autologous blood patch (ABP) intervention trial for patients who underwent lung resection for cancer to examine its effectiveness in preventing a prolonged air leak. AIM 1: To determine the safety and efficacy of autologous blood patch (ABP) as a means to reduce the rate of prolonged air leak (PAL) after lung cancer resection AIM 2: To prospectively examine variation in morbidity and quality of life between patients with and without a PAL

NCT ID: NCT04850742 Enrolling by invitation - Lung Cancer Clinical Trials

Feasibility of Tracheobronchial Reconstruction Using Bioengineered Aortic Matrices

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

We used a segment of cryopreserved aorta as a graft for reconstruction for long segment tracheobronchial lesion in human.

NCT ID: NCT04708639 Enrolling by invitation - Lung Cancer Clinical Trials

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

MonAlec
Start date: June 19, 2019
Phase:
Study type: Observational

Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.

NCT ID: NCT04465214 Enrolling by invitation - Prostate Cancer Clinical Trials

Mobile Sensor Technologies to Assess General Symptomology of People With Cancer

Start date: November 23, 2020
Phase:
Study type: Observational

Background: Many digital devices, such as smartphones and activity monitors, have sensors to collect and track health data. Researchers believe these devices may be able to transform the quality of clinical research and healthcare. They believe they may be able to help assess the symptoms, response to therapy, and quality of life of people with cancer. Objective: To collect data from people with cancer using an Apple iPhone alone or together with an Apple Watch in order to assess their symptoms and activity levels. Eligibility: People ages 18 years and over who have cancer and receiving treatment for their cancer in another NIH protocol Design: Participants will be screened with their medical records. Participants will have a baseline visit. They will have visits every 2 4 weeks based on the treatment protocol in which they are co-enrolled. Then they will have a follow-up visit 4 months after the baseline visit. Visits include: Medical history Physical exam Karnofsky Performance Scale/Eastern Cooperative Oncology Group performance status to see how their disease affects daily activities The study team will use an iPhone to collect data. This includes a 6-minute walk test and tests of hearing, reaction time, and cognitive status. Questionnaires If participants have an iPhone, an Apple Watch will be provided to them after training at the baseline visit. Continuous measurement of their activity will be recorded by the watch between 2 visits. They will wear the watch while they are on study. They will wear the watch while it is not being charged. They should charge the watch at night time. They will have the watch for 4 months.

NCT ID: NCT04366661 Enrolling by invitation - Lung Cancer Clinical Trials

Iraqi Trial for Lung Cancer Screening

ITLUCAS
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

Lung cancer is a global problem. Worldwide, 1.2 million people die of lung cancer each year. In Iraq, lung cancer is the most common malignancy after breast cancer and the leading cause of cancer-related death. Tobacco smoking plays a major role in lung cancer; it is reported in 85-90% of lung cancer patients yet environmental tobacco smoke, environmental and domestic air pollution, work-related risk factors, radon exposure, and viruses may also have an impact on lung cancer incidence rates. Early detection of the disease before patients develop symptoms considers the best way to improve patient outcomes. IT LUCAS is designed to evaluate the utility of low-dose computed tomography (LDCT) screening in early detection and management of lung cancer in high-risk people.

NCT ID: NCT04191174 Enrolling by invitation - Lung Cancer Clinical Trials

Ventilation Heterogeneity Prior to Lung Resection

Start date: January 6, 2020
Phase:
Study type: Observational

This is a single centre prospective six-week observational study to understand the prevalence and clinical relevance of abnormal ventilation of the lung (assessed by Technegas ventilation single photon emission computed tomography (V SPECT) and hyperpolarized 129Xe magnetic resonance imaging (MRI)), in the presence or absence of airway inflammation (assessed by sputum cell counts), in lung cancer patients prior to lung resection surgery.

NCT ID: NCT03535766 Enrolling by invitation - Lung Cancer Clinical Trials

An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions

TRACE
Start date: April 17, 2018
Phase:
Study type: Observational

This study is a single center, minimal risk, physician initiated retrospective chart review. An analysis of treatment timelines for patients diagnosed with lung cancer within the St. Elizabeth system from January 2013 until study completion. The study investigator and designee(s) will review patient electronic medical records, extracting data related to the symptom presentation, diagnosis, and treatment of new diagnoses of lung cancer. Collected data will focus on dates of encounters, diagnostic imaging/procedures, and treatments, with data analysis evaluating time between care encounters and potential delays in care. The data will be further stratified based on system-wide changes implemented to improve efficiency, patient outcomes, and patient experience.

NCT ID: NCT02422628 Enrolling by invitation - Lung Cancer Clinical Trials

Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC

Start date: April 2015
Phase: N/A
Study type: Observational

Correlation of epithelial growth factor receptor mutation in blood of lung cancer patient and clinical outcome.

NCT ID: NCT01585545 Enrolling by invitation - Lung Cancer Clinical Trials

Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers

Start date: October 2013
Phase:
Study type: Observational

The purpose of this study is to evaluate relationships between multiparametric imaging biomarkers and genetic analysis in NSCLC patients.

NCT ID: NCT01551082 Enrolling by invitation - Lung Cancer Clinical Trials

Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes

Start date: March 2012
Phase: N/A
Study type: Observational

Discharging patients home with air leak and chest tube to portable drainage device after thoracic resection is cost effective and safe without compromising patients outcome or satisfaction. Despite good outcomes this practice is not done universally by thoracic surgeons.